Hotgen to Present Innovative Immunodiagnostic Solutions at ADLM 2026
Beijing Hotgen Biotech is set to showcase its latest immunodiagnostic solutions at the ADLM 2026 conference. The company aims to highlight its proprietary technology platforms and global product portfolio in the in vitro diagnostics sector.
Why it matters
Advancements in diagnostic technology are critical for improving clinical laboratory efficiency and global healthcare outcomes.
Newswise — Beijing Hotgen Biotech Co., Ltd. (SSE Code: 688068) will participate in ADLM 2026 and showcase its innovative immunodiagnostic solutions at Booth 4020 . As an innovative company dedicated to the in vitro diagnostics (IVD) field, Hotgen is committed to providing clinical laboratories and healthcare institutions with accurate and efficient diagnostic solutions through advanced technologies.
Founded in 2005, Hotgen continuously advances innovation in immunodiagnostics based on eight proprietary technology platforms. The company has established a comprehensive product portfolio centered on chemiluminescence immunoassay , complemented by point-of-care testing (POCT) and rapid testing products , providing diversified diagnostic solutions for various healthcare scenarios worldwide.
At ADLM 2026 , Hotgen will showcase the following innovative products:
In addition, Hotgen will showcase its colloidal gold rapid testing products and ELISA product portfolio , further meeting diverse diagnostic needs across different healthcare institutions and application scenarios.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in